Efgartigimod for immune checkpoint inhibitor induced polyradiculoneuropathy and cardiomyopathy: A case report. (2025)

Immune checkpoint inhibitors (ICIs) play a crucial role in cancer therapy by enhancing anti-tumor immune responses. However, they may also induce immune-related adverse events (irAEs) such as polyradiculoneuropathy (PRN) and cardiomyopathy, which, although rare, can be life-threatening. Traditional treatments, including corticosteroids and intravenous immunoglobulin (IVIG), often show limited efficacy, underscoring the need for alternative therapeutic strategies. The present study reported the case of a 63-year-old female diagnosed with pancreatic ductal adenocarcinoma who developed profound neurological and cardiac dysfunction, including bilateral ptosis, limb weakness and dysphagia, following chemotherapy and ICI therapy. Initial immunotherapy with IVIG and corticosteroids resulted in on